MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S.

宾夕法尼亚州马尔文，2024年6月26日（环球通讯社）--通过IBN-Annovis Bio Inc.（纽约证券交易所：ANVS）（“Annovis”或“公司”），一家晚期临床药物平台公司，开创了阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的转化疗法，宣布向美国提交新的物质组成专利。

Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability.

专利和商标局涵盖了新型固体形式的buntanetap，选择了最好的晶体，并在2023年6月提交的临时专利的基础上进行了改进。该专利涵盖了新型晶体形式的buntanetap及其用于治疗和/或预防各种神经退行性疾病的用途。结晶形式比不太结构化的形式具有显着优势，包括更好的溶解度和稳定性。

The most stable crystal form of buntanetap (CAS# 3032752-92-1) has been selected as the new lead compound for animal bridge studies and for developing a manufacturing process. The bridge studies were submitted to the FDA and will be discussed in July. The goal is to continue development of our drug and file the NDA with the new crystal form.“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company.

buntanetap（CAS#3032752-92-1）的最稳定晶体形式已被选为动物桥梁研究和开发制造工艺的新先导化合物。桥梁研究已提交给FDA，将于7月讨论。我们的目标是继续开发我们的药物，并用新的晶体形式提交NDA。“我们药物的新固体形式buntanetap的发明以及随后的专利申请代表了我们公司的突破性里程碑。

This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug's properties, ultimately providing greater benefits to our patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. A composition of matter patent comes with protection for the new buntanetap crystalline form and all its uses for a 20-year term.

这一成就将使我们不仅能够继续推进我们的生产线，而且能够增强药物的特性，最终为我们的患者提供更大的益处，”Annovis创始人、总裁兼首席执行官Maria Maccecchini博士说。物质成分专利对新的buntanetap晶型及其所有用途具有20年的保护期。

The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug because it provides adequa.

对于任何开发新药的制药公司来说，物质成分专利是最重要的专利，因为它提供了一种技术。